Pregnancy and oral contraceptives in congenital bleeding disorders of the vitamin K-dependent coagulation factors.
Pregnancies and deliveries represent important hemostatic challenges for congenital coagulation disorders. The same is true for the assumption of oral contraceptives. Available information mainly deals with von Willebrand's disease, factor XI (FXI) deficiency and carriers of hemophilia A. Data concerning patients with congenital prothrombin complex factor deficiencies are very scanty. In the present study, data of a total of 27 women are presented, 11 patients with homozygous or double heterozygous deficiencies of FII, FVII and FX, together with 16 cases of hemophilia B carriers. The patients with FII, FVII or FX defects had a total of 14 pregnancies and often needed transfusion therapy. Proper management resulted in a decrease in postpartum bleeding and satisfactory fetal outcome. Elective cesarean delivery seems indicated only in recent years. Carriers of hemophilia B had a total of 19 pregnancies but showed no bleeding and needed no substitutive therapy. Searching the literature, we discovered only 9 additional patients with prothrombin deficiency or FX deficiency, having a total of 16 pregnancies. On the contrary, there were at least 17 additional patients with FVII deficiency, with a total of 21 pregnancies. The management of the diseases has been variable, but in substantial agreement with the personal observations. Oral contraceptive therapy was administered in some of our patients and in a few additional cases described in the literature. Medication was always well tolerated and patients who took it for a long period of time showed a decrease in menometrorrhagia and an improvement in hematocrit levels. This led to a decrease in transfusional needs and to improved general conditions.
Girolami
Antonio
A
Department of Medical and Surgical Sciences, University of Padua Medical School, Padua, Italy. antonio.girolami@unipd.it
Randi
Maria Luigia
ML
Ruzzon
Elisabetta
E
Lombardi
Anna Maria
AM
Girolami
Bruno
B
Fabris
Fabrizio
F
D000328:Adult; D020147:Coagulation Protein Disorders / Q000150:complications / Q000151:congenital; D003276:Contraceptives, Oral / Q000008:administration & dosage*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008595:Menorrhagia / Q000517:prevention & control*; D008796:Metrorrhagia / Q000517:prevention & control*; D006473:Postpartum Hemorrhage; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000517:prevention & control; D011256:Pregnancy Outcome; D012189:Retrospective Studies; D014812:Vitamin K
D003276:Contraceptives, Oral; D014812:Vitamin K